Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker to spin off spinal implant business, as Viscogliosi Brothers-owned VB Spine
Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to divest its international enterprises in the months to come. | Stryker is selling off its spine implant business—starting with a plan to spin off its U.
Stryker to sell spine business: 8 notes for ASCs
Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a strategic partner to Stryker with exclusive access to the company's Mako Spine and Copilot technology.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
Stryker Corporation SYK recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker to Sell Spinal Implants Business to Viscogliosi Brothers
Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City-based Viscogliosi Brothers specializes in neuro-musculoskeletal treatments.
Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
Lake Street analyst Brooks O’Neil notes that Stryker (SYK) announced a definitive agreement for the sale of its U.S. spinal implants business
StockStory.org on MSN3h
Stryker (NYSE:SYK) Posts Better-Than-Expected Sales In Q4
Medical technology company Stryker (NYSE:SYK) reported in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its ...
Stryker to sell spinal implants business
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.
Strategic Sale: James Andrew Pierce Decides To Exercise Options Worth $2.84M At Stryker
What Happened: Pierce, Group President at Stryker, made a strategic move by exercising stock options for 9,455 shares of SYK as detailed in a Form 4 filing on Thursday with the U.S. Securities and ...
Sales Growth, Strategic Acquisitions Drive Stryker Higher
Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.
Stryker’s Strong Financial Performance and Strategic Moves Justify Buy Rating
In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...
A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Stryker forecasts 2025 profit above estimates on robust demand for surgical devices
Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices. Medical and ...
Stryker reports 2024 operating results and 2025 outlook
Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Full Year Results “We delivered another year of double-digit organic sales growth ...